The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 1 - 10 of 17
What can modelling tell us about the scale-up of CAB for PrEP?
This factsheet summarises the results of mathematical modelling exercises of Cabotegravir (CAB) for PrEP rollout undertaken by researchers affiliated with the HIV Modelling Consortium. These results can help implementers and policymakers understand what to expect and guide early policy decisions to ensure CAB for PrEP is able to have maximum impact on reducing the HIV…
Research, Service Delivery, Testing
MOSAIC HIV Drug Resistance Monitoring Program
MOSAIC’s HIV Drug Resistance (HIVDR) Monitoring Program monitors HIVDR in PrEP seroconverters in project-based and national roll-out programs in sub-Saharan Africa. Activities include: Laboratory research to improve HIVDR testing assays and test diverse sample types for HIVDR using sensitive methods. Technical support and policy guidance for HIVDR assessment in seroconverters to PrEP programs. Implementation of…
Monitoring & Evaluation, Testing
Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally
This article from PLOS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.
Normative Guidance/Policies, Research, Service Delivery, Testing
Long-acting injectable cabotegravir for HIV prevention: WHO guidelines, implementation considerations, and project examples
Recording During this 90-minute webinar, speakers will provide an overview of the new WHO guidelines on CAB for PrEP, discuss implementation issues specifically relating to HIV testing and drug resistance, and highlight examples of planned implementation projects in sub-Saharan Africa and Asia. This webinar is presented by the Global PrEP Network, a WHO-led forum designed…
Research, Normative Guidance/Policies, Testing
PrEP and HIV Drug Resistance Training Slides for Healthcare Workers
These training slides can be used to educate healthcare workers about the risks of HIV drug resistance and PrEP and how to monitor potential resistance.
Service Delivery, Testing
HIV Drug Resistance Monitoring Protocol Template
This template can be used to develop a protocol to monitor HIV drug resistance among seroconversions in users of PrEP.
Monitoring & Evaluation, Testing
Long-Acting Injectable Cabotegravir for HIV Prevention: What do we know and need to know about the risks and consequences of cabotegravir resistance?
This article from The Science of Prevention summarizes what is known about cabotegravir (CAB) pharmacokinetics, activity, and emergence of resistance from in vitro, macaque and clinical studies, and evaluates the risk of resistance from CAB for PrEP with on-time injections and after CAB for PrEP discontinuation.
Monitoring & Evaluation, Research, Testing
Modelling Impact of Injectable Cabotegravir for PrEP on Drug Resistance
An important consideration in the scale-up of injectable cabotegravir (CAB) for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on…
Financing & Costing, Testing
HIV Testing and Injectable Cabotegravir (CAB for PrEP) Introduction: What are the implications for HIV prevention scale-up and the HIV response?
One challenge which has emerged with the introduction of CAB for PrEP is the risk of Integrase Strand Transfer Inhibitor (INSTI) resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers,…
A Pilot Evaluation of Expedited Partner Treatment and Partner HIV Self-testing Among Adolescent Girls and Young Women Diagnosed with Chlamydia trachomatis and Neisseria gonorrhoeae in Kisumu, Kenya
This article describes a pilot study among young women receiving PrEP who were diagnosed with Chlamydia trachomatis or Neisseria gonorrhoeae which found high acceptability and uptake of expedited partner treatment and partner HIV self-testing.